Pulse Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on September 25, 2017, reporting events occurring on September 24, 2017. The Company is an emerging growth company incorporated in Nevada.
Key Financial Metrics
The filing details a private placement transaction rather than periodic financial performance. Key transaction metrics include:
- Shares Issued: 2,000,000 shares of Common Stock.
- Price Per Share: $15.02.
- Total Proceeds: $30,040,000 (calculated from share count and price).
- Use of Proceeds: Working capital and general corporate purposes.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is a transactional report.
Material Changes
The primary material change is the entry into a Securities Purchase Agreement with Robert W. Duggan. This transaction results in the issuance of unregistered equity securities to an accredited investor under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.
Outlook, Risks, and Unusual Items
Registration Rights: The Company granted registration rights to the Investor. A registration statement for resale will be filed no earlier than January 2, 2018, when commercially reasonable.
Risks and Contingencies: The shares sold are unregistered and may not be offered or sold in the United States absent registration or an exemption. The Investor represented the shares are for investment only and not for resale.
Investor Verification Checklist
- Verify the closing of the $30.04 million private placement and receipt of funds.
- Confirm the filing of the registration statement for resale by January 2, 2018.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and limitations.
- Check subsequent filings for updates on the use of proceeds and capital structure changes.